J&J, Vivus patent suit ends

Share this article:

Johnson & Johnson's Janssen subsidiary has walked away from a lawsuit against drugmaker Vivus over patents using the anti-seizure medication topiramate for a variety of medical conditions.

Vivus, in turn, has agreed to pay a one-time fee and royalty on its FDA-approved weight-loss drug Qsymia, which combines phentermine and topiramate.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Business Briefs

Novartis said to be stepping out of HCV

Novartis is said to have relinquished rights to an investigational hep. C treatment, signaling its exit from the therapeutic space, according to a former partner's announcement.

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies

Kantar acquires Evidências, expands Brazilian presence

The company's acquisition signals the growing importance of understanding the Brazilian healthcare market and evidence-based healthcare management services.